Seeking Alpha

Novartis Q4 earnings miss expectations

  • Novartis's (NVS) Q4 adjusted EPS dropped 3% to $1.20 and missed consensus by $0.08, affected by currency fluctuations.
  • Net income increased to $2.06B from $2.02B and also fell short of forecasts of $2.4B.
  • Sales rose 2% to $15.08B and almost met expectations of $15.09B, with revenue lifted by recently-launched products and strong sales in China and Russia.
  • Novartis projected that 2014 sales will grow by a low- to mid-single-digit percentage in constant currencies, assuming that a competitor to the company's blockbuster blood-pressure drug Diovan is launched at the start of Q2.
  • Novartis also predicted that core operating income will rise more than sales
  • Sales breakdown: pharmaceutical division +1% to $8.3B; Alcon eye-care unit +3% to $2.7B
  • Proposes dividend of 2.45 Swiss francs ($2.72) per share for 2014, up 7%. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: